A Prospective Protocol of Stereotactic Body Irradiation With Concurrent Intraprostatic Lesion Boost Utilizing Intensity Modulated Radiotherapy for Patients With Low- and Intermediate-Risk Prostate Cancer
Standard external beam radiation therapy (EBRT) for low- to intermediate-risk prostate
cancer involves several weeks of daily treatment sessions. Stereotactic body radiation
therapy (SBRT) is a newer form of EBRT that gives fewer treatments but higher doses of
radiation per treatment. In many patients there are certain areas within the prostate with
more prominent cancerous growth (intraprostatic lesions), which may require higher doses of
radiation (boost) to treat effectively. This study will treat the prostate with
simultaneous boost(s) to intraprostatic lesion(s) in 5 treatments over 10-14 days.
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Biochemical disease-free survival
Biochemical Disease-Free Survival (bDFS), the time from completion of protocol treatment to the documented PSA rise of 2 ng/mL above the PSA nadir reached after treatment.
Charles Leonard, MD
Rocky Mountain Cancer Centers
United States: Institutional Review Board
|Rocky Mountain Cancer Centers - Aurora||Aurora, Colorado 80012|
|Rocky Mountain Cancer Centers - Littleton||Littleton, Colorado 80120|